Skip to main content
Top
Published in: Annals of General Psychiatry 1/2020

01-12-2020 | Psychotherapy | Review

MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t

Author: Louise Morgan

Published in: Annals of General Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

PTSD is a chronic condition with high rates of comorbidity, but current treatment options are limited and not always effective. One novel approach is MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD, where MDMA is used as a catalyst to facilitate trauma processing during psychotherapy. The aim was to review all current research into MDMA-assisted psychotherapy for PTSD.

Methods

Articles were identified through PubMed and Science Direct for items published up to 31st March 2019 using terms “treatments for PTSD”, “drug treatments for PTSD”, “MDMA”, “MDMA pathway”, “MDMA-assisted psychotherapy” and “MDMA-assisted psychotherapy for PTSD”. Articles were identified through Google Scholar and subject-specific websites. Articles and relevant references cited in those articles were reviewed.

Results

Small-scale studies have shown reduced psychological trauma, however there has been widespread misunderstanding of the aims and implications of this work, most commonly the notion that MDMA is a ‘treatment for PTSD’, which to date has not been researched. This has harmful consequences, namely dangerous media reporting and impeding research progression in an already controversial field.

Conclusions

MDMA-assisted psychotherapy may help people who have experienced psychological trauma and who have not been able to resolve their problems through existing treatments, however more research is needed. If this is to get appropriate research attention, we must report this accurately and objectively.
Literature
1.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
3.
go back to reference Morris MC, Hellman N, Abelson JL, Rao U. Cortisol, heart rate, and blood pressure as early markers of PTSD risk: a systematic review and meta-analysis. Clin Psychol Rev. 2016;49:79–91.PubMedPubMedCentralCrossRef Morris MC, Hellman N, Abelson JL, Rao U. Cortisol, heart rate, and blood pressure as early markers of PTSD risk: a systematic review and meta-analysis. Clin Psychol Rev. 2016;49:79–91.PubMedPubMedCentralCrossRef
4.
go back to reference Zoladz PR, Diamond DM. Current status on behavioral and biological markers of PTSD: a search for clarity in a conflicting literature. Neurosci Behav Rev. 2013;37(5):860–95.CrossRef Zoladz PR, Diamond DM. Current status on behavioral and biological markers of PTSD: a search for clarity in a conflicting literature. Neurosci Behav Rev. 2013;37(5):860–95.CrossRef
6.
go back to reference Cloitre M. Effective psychotherapies for posttraumatic stress disorder: a review and critique. CNS Spectr. 2009;14:32–43.PubMed Cloitre M. Effective psychotherapies for posttraumatic stress disorder: a review and critique. CNS Spectr. 2009;14:32–43.PubMed
7.
go back to reference Foa EB, Keane TM, Friedman MJ, Cohen JA. Effective Treatments for PTSD, Practice Guidelines from the International Society for Traumatic Stress Studies. New York: Guilford Press; 2009. Foa EB, Keane TM, Friedman MJ, Cohen JA. Effective Treatments for PTSD, Practice Guidelines from the International Society for Traumatic Stress Studies. New York: Guilford Press; 2009.
8.
go back to reference Schnyder U. Why new psychotherapies for posttraumatic stress disorder? Psychother Psychosom. 2005;74:199–201.PubMedCrossRef Schnyder U. Why new psychotherapies for posttraumatic stress disorder? Psychother Psychosom. 2005;74:199–201.PubMedCrossRef
9.
go back to reference Zepinic V. Treatment resistant symptoms of complex PTSD caused by torture during war. Can Soc Sci. 2015;11(9):26–32. Zepinic V. Treatment resistant symptoms of complex PTSD caused by torture during war. Can Soc Sci. 2015;11(9):26–32.
10.
go back to reference Doukas A, D’Andrea W, Doran J, Pole N. Psychophysiological predictors of working alliance among treatment-seeking women with complex trauma exposure. J Trauma Stress. 2014;27:672–9.PubMedCrossRef Doukas A, D’Andrea W, Doran J, Pole N. Psychophysiological predictors of working alliance among treatment-seeking women with complex trauma exposure. J Trauma Stress. 2014;27:672–9.PubMedCrossRef
12.
go back to reference Guthrie RM, Bryant RA. Extinction learning before trauma and subsequent posttraumatic stress. Psychosom Med. 2006;68(2):307–11.PubMedCrossRef Guthrie RM, Bryant RA. Extinction learning before trauma and subsequent posttraumatic stress. Psychosom Med. 2006;68(2):307–11.PubMedCrossRef
13.
go back to reference Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99:20–35.PubMedCrossRef Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99:20–35.PubMedCrossRef
14.
go back to reference Foa EB. Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences: therapist guide. New York: Oxford University Press; 2007.CrossRef Foa EB. Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences: therapist guide. New York: Oxford University Press; 2007.CrossRef
15.
go back to reference Jaycox LH, Foa EB, Morral AR. Influence of emotional engagement and habituation on exposure therapy for PTSD. J Consult Clin Psychol. 1998;66:185–92.PubMedCrossRef Jaycox LH, Foa EB, Morral AR. Influence of emotional engagement and habituation on exposure therapy for PTSD. J Consult Clin Psychol. 1998;66:185–92.PubMedCrossRef
16.
go back to reference Bedi G, Hyman D, De Wit H. Is ecstasy an empathogen? Effects of ± 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68:1134–40.PubMedPubMedCentralCrossRef Bedi G, Hyman D, De Wit H. Is ecstasy an empathogen? Effects of ± 3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68:1134–40.PubMedPubMedCentralCrossRef
17.
go back to reference Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2012;219:109–22.PubMedCrossRef Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2012;219:109–22.PubMedCrossRef
18.
go back to reference Wolff K, Tsapakis EM, Winstock AR, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol. 2006;20:400–10.PubMedCrossRef Wolff K, Tsapakis EM, Winstock AR, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol. 2006;20:400–10.PubMedCrossRef
19.
go back to reference Dumont GJ, Sweep FC, Van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4:359–66.PubMedCrossRef Dumont GJ, Sweep FC, Van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4:359–66.PubMedCrossRef
20.
go back to reference Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology. 2000;23:388–95.PubMedCrossRef Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology. 2000;23:388–95.PubMedCrossRef
21.
go back to reference Bestha D, Soliman L, Blankenship K, Rachal J. The walking wounded: emerging treatments for PTSD. Curr Psychiatry Rep. 2018;20:94.PubMedCrossRef Bestha D, Soliman L, Blankenship K, Rachal J. The walking wounded: emerging treatments for PTSD. Curr Psychiatry Rep. 2018;20:94.PubMedCrossRef
22.
go back to reference Metzner R, Adamson S. Using MDMA in healing, psychotherapy and spiritual practice. In: Holland J, editor. Ecstasy, a complete guide: a comprehensive look at the risks and benefits of MDMA. Rochester: Inner traditions; 2001. p. 182–207. Metzner R, Adamson S. Using MDMA in healing, psychotherapy and spiritual practice. In: Holland J, editor. Ecstasy, a complete guide: a comprehensive look at the risks and benefits of MDMA. Rochester: Inner traditions; 2001. p. 182–207.
23.
25.
go back to reference Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013;27(1):28–39.PubMedPubMedCentralCrossRef Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013;27(1):28–39.PubMedPubMedCentralCrossRef
26.
go back to reference Feduccia AA, Holland J, Mithoefer MC. Progress and promise for the MDMA drug development program. Psychopharmacology. 2018;235(2):561–71.PubMedCrossRef Feduccia AA, Holland J, Mithoefer MC. Progress and promise for the MDMA drug development program. Psychopharmacology. 2018;235(2):561–71.PubMedCrossRef
27.
go back to reference Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(1):221–8.PubMedCrossRef Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(1):221–8.PubMedCrossRef
29.
go back to reference Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013;14:577–85.PubMedCrossRef Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013;14:577–85.PubMedCrossRef
33.
go back to reference Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27(1):40–52.PubMedCrossRef Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27(1):40–52.PubMedCrossRef
35.
go back to reference Bedi G. 3,4-methylenedioxymethamphetamine as a psychiatric treatment. JAMA Psychiatry. 2018;75(5):419–20.PubMedCrossRef Bedi G. 3,4-methylenedioxymethamphetamine as a psychiatric treatment. JAMA Psychiatry. 2018;75(5):419–20.PubMedCrossRef
36.
go back to reference Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacology. 2018;9:733.CrossRef Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacology. 2018;9:733.CrossRef
37.
go back to reference Sessa B. MDMA and PTSD treatment “PTSD: from novel pathophysiology to innovative therapeutics”. Neurosci Lett. 2017;649:176–80.PubMedCrossRef Sessa B. MDMA and PTSD treatment “PTSD: from novel pathophysiology to innovative therapeutics”. Neurosci Lett. 2017;649:176–80.PubMedCrossRef
38.
go back to reference Fattore L, Piva A, Zanda MT, Fumagalli G, Chiamulera C. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Psychopharmacology. 2018;235(2):433–45.PubMedCrossRef Fattore L, Piva A, Zanda MT, Fumagalli G, Chiamulera C. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Psychopharmacology. 2018;235(2):433–45.PubMedCrossRef
39.
go back to reference White CM. 3,4-Methylenedioxymethamphetamine’s (MDMA’s) impact on posttraumatic stress disorder. Ann Pharmacother. 2014;48(7):908–15.PubMedCrossRef White CM. 3,4-Methylenedioxymethamphetamine’s (MDMA’s) impact on posttraumatic stress disorder. Ann Pharmacother. 2014;48(7):908–15.PubMedCrossRef
40.
go back to reference Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacolog. 2016;30(7):595–600.CrossRef Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. J Psychopharmacolog. 2016;30(7):595–600.CrossRef
41.
go back to reference Parrott ACMDMA. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014). Hum Psychopharmacol Clin Exp. 2014;29:109–19.CrossRef Parrott ACMDMA. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014). Hum Psychopharmacol Clin Exp. 2014;29:109–19.CrossRef
43.
go back to reference Sessa B. Could MDMA be useful in the treatment of post-traumatic stress disorder? Prog Neurol Psychiatry. 2011;15:4–7.CrossRef Sessa B. Could MDMA be useful in the treatment of post-traumatic stress disorder? Prog Neurol Psychiatry. 2011;15:4–7.CrossRef
45.
go back to reference Parrott AC. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Hum Psychopharmacol Clin Exp. 2013;28:289–307.CrossRef Parrott AC. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Hum Psychopharmacol Clin Exp. 2013;28:289–307.CrossRef
46.
go back to reference Parrott AC. The potential dangers of using MDMA for psychotherapy. J Psychoact Drugs. 2014;46(1):37–43.CrossRef Parrott AC. The potential dangers of using MDMA for psychotherapy. J Psychoact Drugs. 2014;46(1):37–43.CrossRef
47.
go back to reference Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:237–49.PubMedCrossRef Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:237–49.PubMedCrossRef
48.
go back to reference Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B. A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘ecstasy’: an overview of 25 years of empirical research”. Hum Psychopharmacol Clin Exp. 2014;29:105–8.CrossRef Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B. A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘ecstasy’: an overview of 25 years of empirical research”. Hum Psychopharmacol Clin Exp. 2014;29:105–8.CrossRef
51.
go back to reference Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3:481–8.PubMedCrossRef Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016;3:481–8.PubMedCrossRef
53.
go back to reference Schuldt FM. MDMA-assisted psychotherapy for posttraumatic stress disorder. Diplomartbeit: Universität Wien. Fakultät für Psychologie; 2015. Schuldt FM. MDMA-assisted psychotherapy for posttraumatic stress disorder. Diplomartbeit: Universität Wien. Fakultät für Psychologie; 2015.
Metadata
Title
MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t
Author
Louise Morgan
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Psychotherapy
Published in
Annals of General Psychiatry / Issue 1/2020
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-020-00283-6

Other articles of this Issue 1/2020

Annals of General Psychiatry 1/2020 Go to the issue